StockNews.AI
GILD
StockNews.AI
3 days

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

1. Trodelvy significantly improves outcomes in metastatic triple-negative breast cancer treatment. 2. Combination therapy reduced disease progression risk by 35%, indicating strong efficacy.

2 mins saved
Full Article

FAQ

Why Bullish?

This positive clinical data supports GILD's growth potential, similar to past successes with antiviral treatments.

How important is it?

The successful data from Trodelvy enhances GILD's portfolio, indicating strong future sales opportunities.

Why Long Term?

As patient outcomes improve with new therapies, GILD's revenue potential may increase significantly over time.

Related Companies

MRNAPFEABBV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care Keytruda plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 mo.

Related News